Company Analysis
Sign in

Cellectis S.A. (CLLS)

Nasdaq: CLLS · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2014
Full chart Alerts Compare
Grade5.6
◀ Past 4.9● Present 5.4▶ Future 6.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

115 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cellectis S.A.’s names, not what it holds today.

Patents granted
115
115 utility, 1976 to Dec 31, 2025
Granted in 2025
5
Against 11 in 2024 and 12 in 2023
Applications published
244
11 of them in 2025
Names they are printed under
3
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology31
Pharmaceuticals10
Medical technology7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
CELLECTIS its own name
FR, as the owner printed on each patent
97 granted
95 published
CELLECTIS its own name
named as the applicant on its applications, in FR
0 granted
127 published
CELLECTIS SA its own name
FR, as the owner printed on each patent
18 granted
22 published
Names not counted (1)
Cellectis S.A.
Most of its patents print DE; this name counts in FR. 1 granted and 0 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 19, 202512,391,933Targeted gene insertion for improved immune cells therapyMedical technologyCELLECTIS
Jul 22, 202512,365,733Method for improving production of car T cellsMedical technologyCELLECTIS
Mar 18, 202512,252,699Method for generating t-cells compatible for allogenic transplantationBiotechnologyCELLECTIS
Feb 11, 202512,221,478Targeted gene integration of CRS inhibitor genes for improved immune cells therapyBiotechnologyCELLECTIS
Jan 28, 202512,209,125Targeted gene integration of NK inhibitors genes for improved immune cells therapyBiotechnologyCELLECTIS
Dec 24, 202412,171,820Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironmentPharmaceuticalsCELLECTIS
Nov 19, 202412,144,825Cellular immunotherapy for repetitive administrationMedical technologyCELLECTIS
Nov 5, 202412,133,867Universal anti-CD22 chimeric antigen receptor engineered immune cellsBiotechnologyCELLECTIS SA
Jun 18, 202412,012,607Engineering wheat with increased dietary fiberBiotechnologyCELLECTIS
May 21, 202411,987,639Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapyBiotechnologyCELLECTIS
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361301METHOD FOR IMPROVING PRODUCTION OF CAR T CELLSMedical technologyCELLECTIS
Nov 13, 20252025/0345364CISH GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPYBiotechnologyCELLECTIS
Sep 18, 20252025/0288673GENE THERAPY FOR THE TREATMENT OF ACTIVATED PI3KINASE DELTA SYNDROME TYPE 1 (APDS1)BiotechnologyCELLECTIS
Sep 11, 20252025/0281613ENHANCING SAFETY OF T-CELL-MEDIATED IMMUNOTHERAPYMedical technologyCELLECTIS
Sep 4, 20252025/0277231METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATIONBiotechnologyCELLECTIS
Jun 12, 20252025/0188483METHODS FOR NON-TRANSGENIC GENOME EDITING IN PLANTSBiotechnologyCELLECTIS
Apr 24, 20252025/0129377ENGINEERING WHEAT WITH INCREASED DIETARY FIBERBiotechnologyCELLECTIS
Feb 20, 20252025/0057952ENHANCING EFFICACY OF T-CELL-MEDIATED IMMUNOTHERAPY BY MODULATING CANCER-ASSOCIATED FIBROBLASTS IN SOLID TUMORSMedical technologyCELLECTIS
Jan 30, 20252025/0034641CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATIONMedical technologyCELLECTIS
Jan 23, 20252025/0026808UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLSBiotechnologyCELLECTIS SA
What it applied for, 2024 to 2025: Biotechnology 17 · Medical technology 5 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CLLS · research, not advice